Von Willebrand factor (VWF) is a blood protein that helps platelets stick to injured vessel walls and protects clotting factor VIII. A VWF panel measures how much of the protein is present and how well it works, which helps a clinician explain unusual bruising or bleeding. Levels vary, so one result rarely settles it.
Von Willebrand factor is a large protein that acts as both the glue and the bodyguard of early clot formation, tethering platelets to a damaged vessel wall and carrying clotting factor VIII through the bloodstream 1.
It is made by the cells lining blood vessels and by the bone marrow cells that produce platelets, stored in specialised granules, and released when a vessel is injured or the vessel lining is activated 3. In plasma it circulates as strings of repeating units called multimers. The longer the multimer, the better it captures platelets, and a plasma enzyme called ADAMTS13 trims the longest strings so clot formation stays proportionate to the injury 3.
Two mechanics matter. The first is adhesion. In small, fast-flowing vessels, blood moves with enough shear force that platelets cannot grip exposed collagen on their own. VWF unfolds under that shear, binds collagen at one end and a platelet surface receptor at the other, and holds the first platelets in place long enough for a plug to form 1. That is why a shortfall in VWF tends to show up as bleeding from thin, high-shear surfaces such as the nose, gums, gut lining and uterus.
The second is protection. Factor VIII travels bound to VWF, which shields it from early clearance and delivers it to the site of injury 1. When VWF runs low, factor VIII often drifts down with it, so a VWF problem can look at first glance like a factor VIII problem on screening tests.
Because VWF sits at the junction between vessel wall biology and the clotting cascade, it is always read alongside other coagulation results rather than on its own.
It matters because VWF sets how fast small injuries stop bleeding, and a shortfall in it is the most common inherited cause of abnormal bleeding 2.
Most of the time the system is invisible. A paper cut seals, a bruise fades, a dental cleaning passes without incident. The protein only announces itself when the system is stressed, which is why a mild deficiency can go unnoticed for decades and then surface after a tooth extraction, a surgical procedure, childbirth, or a run of unusually heavy menstrual periods. Clinicians often describe the pattern as mucocutaneous, meaning skin and mucous membranes rather than deep joints and muscles 1.
There is a second reason the marker is useful. Knowing a person's VWF status changes how a care team plans ahead. Procedures, pregnancies and injuries are all easier to manage when the bleeding risk is known in advance rather than discovered during the event, and specialist guidance emphasises planning around the diagnosis 7. Any such planning belongs to a licensed provider who knows the full clinical picture.
The other direction matters too. VWF is not only a bleeding marker. It rises with inflammation and with activation of the blood vessel lining, so a high value is read as a signal about vascular stress rather than a bleeding problem 3. That dual role is what makes the number interesting to anyone tracking long-term vascular health, not just to people with a bleeding history.
A platelet count tells you how many platelets are circulating, while VWF testing tells you how well those platelets can stick where they are needed. Bleeding can come from too few platelets, from platelets that do not function well, or from a missing adhesive protein, so the two results are read together. In most people with a VWF shortfall the platelet count is unremarkable, with one exception, a subtype in which VWF binds platelets too avidly and the count can run low 2. For how the platelet count is measured, what its reference and optimal ranges are, and what a high or low count may reflect, see the dedicated guide to Platelets.
The panel usually combines three first-line results, the amount of protein, how well it works, and the factor VIII level it supports 5.
The von Willebrand factor antigen test (written as VWF:Ag) measures quantity. It answers one question, how much of the protein is in the plasma, without saying anything about whether it functions.
The activity test answers the functional question. Historically this was the ristocetin cofactor assay, which uses a reagent that forces VWF to bind platelets in a test tube. Newer platelet-binding assays using recombinant receptor fragments, reported as GPIbM or GPIbR methods, are now widely used because the older method carries more variability at low levels 4.
Factor VIII activity (FVIII:C) completes the trio, since VWF is the carrier protein for factor VIII 1.
The relationship between the numbers carries as much information as the numbers themselves. When activity and antigen fall together, the picture suggests less protein of normal quality. When activity sits well below antigen, the picture suggests protein that is present but working poorly, and laboratories use the activity to antigen ratio to flag that pattern for further testing 4.
Second-line testing is where subtypes get sorted out. Collagen binding assays, multimer analysis, factor VIII binding assays, ristocetin-induced platelet agglutination and targeted genetic sequencing are each used to separate one subtype from another, and a specialist laboratory usually runs them in sequence rather than all at once 5.
Most laboratories report VWF results in international units per decilitre, with typical adult reference intervals spanning roughly half to twice the average level.
| Test | What it reflects | Typical lab reference range |
|---|---|---|
| VWF antigen (VWF:Ag) | How much VWF protein is in plasma | About 50 to 200 IU/dL |
| VWF platelet-binding activity (VWF:RCo, GPIbM or GPIbR) | How well the protein grips platelets | About 50 to 200 IU/dL |
| Factor VIII activity (FVIII:C) | The clotting factor VWF carries | About 50 to 150 IU/dL |
| Activity to antigen ratio | Quality versus quantity of the protein | Above about 0.7 |
These are typical lab reference ranges. They vary by laboratory, assay method, age and sex, so always read a result against the interval printed on your own report.
For the companion count that appears on the same requisition, FitScript publishes an optimal range alongside the standard one.
| Marker | Standard lab reference range | FitScript optimal range |
|---|---|---|
| Platelet count | 150 to 400 K/µL | 150 to 300 K/µL |
Optimal ranges are optimization targets, not diagnostic cut-offs, and a value outside one is a prompt for a conversation rather than a conclusion.
Two interpretive thresholds are worth knowing. Current diagnostic guidance regards levels below 30 IU/dL as consistent with von Willebrand disease, while levels between 30 and 50 IU/dL are labelled low VWF and are interpreted against the person's bleeding history rather than treated as a diagnosis in themselves 5.
A low result means less functional adhesive protein was available in that sample, which may reflect an inherited shortfall, an acquired one, or a transient dip, and only a clinician can sort out which.
The inherited explanation is the most common. Von Willebrand disease is described in the literature as the most frequent inherited bleeding disorder, and in its mild forms it is easy to overlook because the bleeding is everyday rather than catastrophic 2. A single low value is not a diagnosis. Diagnosis rests on repeated laboratory results read together with a structured bleeding history and, where relevant, family history 5.
Levels can also fall later in life without any inherited cause. Acquired von Willebrand syndrome is associated with certain blood and bone marrow disorders, with some heart valve conditions and mechanical circulatory support devices that shear the protein as blood passes through, and with a few autoimmune conditions 3. The practical clue is timing, a new bleeding tendency in adulthood with no childhood history points in that direction.
There is also a boundary zone. Levels in the 30 to 50 IU/dL band sit below the reference interval but above the diagnostic threshold, and guidance describes this as low VWF rather than disease 5. Many people in that band bleed normally. Some do not, particularly around surgery or childbirth.
The sensible next step after a low value is not self-interpretation. It is a repeat panel drawn under better conditions and a conversation with a clinician about your actual bleeding history. Any management decision, including whether a specialist referral is appropriate, belongs to a licensed provider.
A high von Willebrand factor value usually reflects an activated or inflamed blood vessel lining rather than a clotting advantage, and it is read as a context-dependent signal rather than a diagnosis.
The protein behaves as an acute phase reactant, meaning it climbs during infection, inflammation, tissue injury, surgery and pregnancy, and it also rises with age 3. A sample drawn during an illness or shortly after an operation can therefore read high for reasons that have nothing to do with baseline biology, which is one reason repeat testing in a calmer window is standard practice 4.
Elevated VWF is also associated with an increased risk of thrombosis and with markers of cardiovascular disease, reflecting the protein's role in platelet recruitment at the vessel wall 3. That association describes groups of people, not individuals, and it does not translate into a prediction for any one person or into a reason to change anything on your own.
There is a practical catch worth knowing. Because inflammation, stress and pregnancy push VWF upward, a high or high-normal reading can temporarily mask a mild underlying deficiency, which is exactly why a single reassuring value does not close the question in someone with a clear bleeding pattern 4.
The useful observation to carry forward is the trend across several draws taken when you are well, discussed with a clinician who can weigh it against the rest of your panel.
Inherited von Willebrand disease is divided into three broad categories, two quantitative and one qualitative, and the category shapes which second-line tests a laboratory runs 2.
Type 1 is a partial quantitative shortfall. The protein is structurally normal but there is less of it, and this is the most common and generally the mildest presentation 1.
Type 2 covers qualitative defects, where the protein is present in reasonable quantity but does not do its job properly. It splits into four recognised subtypes. In 2A, the largest and most active multimers are missing. In 2B, VWF binds platelets too readily, which can pull the platelet count down. In 2M, binding to platelets or collagen is impaired while multimer structure stays intact. In 2N, the defect sits in the factor VIII binding site 2.
Type 2N deserves a separate mention because it is the easiest to misread. The VWF level can look acceptable while factor VIII runs low, producing a laboratory picture that resembles mild haemophilia A, and distinguishing the two requires a factor VIII binding assay or genetic testing 6.
Type 3 is the near-complete absence of the protein. It is rare and produces the most pronounced bleeding pattern, including joint and muscle bleeding that resembles haemophilia because factor VIII is also very low 1.
Classification is not academic. Subtype determines which laboratory tests are informative and which management options a specialist would consider, and those decisions belong to a licensed provider working from the complete picture 8.
VWF is one of the more volatile proteins in routine coagulation testing, and several ordinary factors shift it enough to change how a result reads.
Blood group is the largest non-disease influence. Research suggests that blood group O is associated with meaningfully lower VWF levels than non-O groups, because of faster clearance of the protein from the circulation, which means a person with group O can sit below the standard reference interval without any underlying disorder 3. Some laboratories report blood group specific intervals for this reason.
Stress and physical exertion push levels up quickly. The protein is released from storage granules in the vessel lining in response to adrenaline and to exercise, so a stressful needle experience, a workout before the draw, or an anxious morning can lift a result out of the range it would otherwise occupy 3.
Hormonal status matters too. Estrogen exposure and pregnancy raise VWF and factor VIII levels, which can normalise a previously low result and complicate testing in people who are pregnant or using estrogen-containing products 3. Levels also shift modestly across the menstrual cycle.
Inflammation, acute illness, recent surgery and advancing age all add upward pressure 3.
Finally, there is the laboratory itself. VWF assays are sensitive to sample handling and show more variation between methods than many routine chemistry tests, particularly at low levels 4.
The implication is simple. Diagnostic guidance calls for repeat testing on separate occasions before drawing conclusions, which is why a single borderline value is a starting point and not an answer 5.
They are connected physically. Factor VIII circulates bound to VWF, and that binding is what keeps factor VIII in the bloodstream long enough to be useful 1.
Unbound factor VIII is cleared rapidly. By carrying it, VWF extends its survival in plasma and concentrates it where platelets are already gathering, so the two proteins arrive at an injury together. The consequence on a lab report is predictable. When VWF is low, factor VIII usually trails downward with it, and in the most severe quantitative forms both are very low 1.
This is also why a clotting screen can point in the wrong direction. A low factor VIII prolongs the activated partial thromboplastin time, the screening test that reflects the intrinsic clotting pathway, and an isolated prolonged result in a person with a bleeding history is one of the common routes into VWF testing.
The trap sits in type 2N, where the binding pocket for factor VIII is faulty. VWF quantity and platelet-binding activity can look acceptable while factor VIII is disproportionately low, producing a result that resembles mild haemophilia A, and only a factor VIII binding assay or genetic testing reliably separates the two 6. Getting that distinction right matters because the inheritance pattern and the specialist approach differ, and the call belongs to a clinician.
Testing is a standard venous blood draw into citrate tubes, but the sample handling around it is unusually consequential, so where and when you get drawn affects the result.
VWF assays are sensitive to how plasma is collected, processed and frozen, and preanalytical problems are a recognised source of falsely low or falsely variable results 4. A difficult draw, a partially filled tube, or a long delay before processing can all distort the picture. Laboratories that run these assays regularly handle them under defined conditions for that reason.
Timing is the part you can influence. A morning draw taken when you are well, rested and not in the middle of an acute illness gives the most representative picture. Strenuous exercise and acute stress shortly beforehand push levels up, and sitting quietly for a few minutes before the needle helps. Fasting is not usually required for coagulation testing, though it may be for other markers drawn at the same visit.
Tell whoever is ordering the panel about pregnancy, recent surgery, current infection and any estrogen-containing products you use, since all of these change how the numbers should be read.
Expect more than one visit. Because levels fluctuate, diagnostic pathways call for confirmation on a separate occasion, and second-line subtype testing is usually ordered only after the first-line panel suggests it is needed 5.
The pattern that prompts testing is repeated, low-impact bleeding from skin and mucous membranes, rather than one dramatic event.
The classic cluster is easy bruising that appears without remembered injury, frequent or prolonged nosebleeds, and heavy menstrual periods that interfere with daily life or lead to low iron. Other prompts include prolonged bleeding after dental extraction, unexpected bleeding during or after surgery, heavier than expected bleeding after childbirth, and gum bleeding with ordinary brushing 1.
Family history carries real weight. Most inherited forms follow an autosomal pattern, so a parent, sibling or child with a similar bleeding history raises the prior probability considerably 2.
Clinicians increasingly formalise this with a structured bleeding assessment tool, a standardised questionnaire that converts a scattered history into a bleeding score, and diagnostic pathways use that score alongside laboratory results to decide who needs testing and how to interpret borderline numbers 5. The tool exists because memory is unreliable. People who have bled this way their whole life tend to describe it as normal.
One caution. Bruising and heavy periods are common and have many explanations, most of which have nothing to do with VWF. The panel answers one specific question, and a clinician decides whether that question is the right one to ask in your case.
VWF results are interpreted inside a wider coagulation picture, so several companion markers are usually drawn at the same visit.
A complete blood count provides the platelet number and the haemoglobin, which together separate a shortage of platelets from a problem with how platelets stick, and flag the anaemia that follows sustained blood loss. Iron studies including ferritin are often added when menstrual or gastrointestinal bleeding is part of the history, since iron depletion is frequently the first measurable consequence of chronic low-grade bleeding.
The standard clotting screen comes next. The activated partial thromboplastin time reflects the intrinsic pathway and can be prolonged when factor VIII is pulled down by low VWF, while the prothrombin time covers the other arm of the cascade. Fibrinogen, the protein that forms the structural mesh of a clot, is measured alongside them, and a low value points toward a different mechanism entirely.
Blood group typing is worth having on file, because group O shifts the expected VWF interval downward.
Specialist laboratories may add platelet function testing, factor VIII binding assays, multimer analysis or genetic sequencing depending on what the first-line panel shows 5. FitScript tests 150+ biomarkers per year and Atlas, its AI health advisor, interprets results in the context of the rest of a member's panel.
Talk to a clinician about any VWF result that sits outside the reference interval, and do it promptly if you also have a bleeding history or a procedure coming up.
The observation to bring is the pattern, not the single number. Note the values across any repeat draws, whether activity tracked with antigen, what the factor VIII level did, and what was happening in your life on the day of each draw, including illness, pregnancy, estrogen exposure, recent surgery or a hard training session.
Some situations deserve a faster conversation. A new bleeding tendency that appears in adulthood with no childhood history, bleeding that is getting worse, a planned surgical or dental procedure, pregnancy, or a result in the low range alongside symptomatic bleeding are all worth discussing with a clinician promptly.
What happens next is usually a repeat panel under controlled conditions, a structured bleeding history, and in some cases referral to a haemostasis specialist who can run subtype testing and plan around procedures 8. Treatment decisions belong to a licensed provider who has examined you and reviewed your full history.
This article is educational and is not medical advice. Discuss your own results, and any next step, with a clinician or licensed provider, and never ignore an out-of-range value because a page on the internet described it as common.
Related reading on other markers drawn with a coagulation workup, fibrinogen covers the protein that forms the structural mesh of a clot, and the guide to the ptt blood test explains the screening test that can be prolonged when factor VIII is pulled down.
It is used to work out whether a bleeding pattern, such as easy bruising or prolonged bleeding after a procedure, involves the protein that anchors platelets to injured vessel walls. The panel measures how much of the protein is present, how well it works, and the factor VIII level it supports. A clinician decides whether the panel is appropriate and what the combination of results means for you.
No, they are two different proteins that travel together. Von Willebrand factor acts as the carrier that keeps factor VIII in the circulation and delivers it to an injury site. Because of that partnership, a low von Willebrand factor level often drags factor VIII down with it, which is why both are measured on the same panel.
A high value most often reflects inflammation, infection, recent surgery, pregnancy or simply a stressful draw, since the protein is released whenever the blood vessel lining is activated. It is not a diagnosis by itself and it is read against the rest of your panel and your clinical picture. The usual next step is a repeat measurement taken when you are well, discussed with a clinician.
Not reliably. Levels swing from week to week, and inflammation, pregnancy or estrogen exposure can lift a result into the normal range temporarily. If your bleeding history is suggestive, a clinician will usually repeat the panel on a separate occasion before drawing any conclusion.
Yes. People with blood group O tend to have lower von Willebrand factor levels than people with other groups, because the protein is cleared from their circulation faster. Some laboratories report blood group specific intervals for this reason, and a clinician will factor your group into the interpretation.
Fasting is not usually required for coagulation testing, though it may be needed for other markers drawn at the same visit. Avoid hard exercise beforehand, sit quietly for a few minutes before the needle, and schedule the draw for a day when you are well rather than during an acute illness. Mention pregnancy, recent surgery and any estrogen-containing products to whoever orders the test.
The uterine lining is one of the surfaces where the protein does most of its work, so a shortfall often shows up as unusually heavy or prolonged menstrual bleeding before anything else does. Heavy periods have many other explanations too, so the panel answers one specific question among several. A clinician decides whether it is the right question in your case.
A single low value is a starting point, not a diagnosis. Expect a repeat panel drawn under controlled conditions, a structured review of your bleeding and family history, and in some cases referral to a specialist laboratory for subtype testing. Any decision about management or follow-up belongs to a licensed provider who has reviewed your full picture.